Fondaparinux overdose: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 6: | Line 6: | ||
Data obtained in patients undergoing chronic intermittent hemodialysis suggest that clearance of Arixtra can increase by 20% during hemodialysis. | Data obtained in patients undergoing chronic intermittent hemodialysis suggest that clearance of Arixtra can increase by 20% during hemodialysis. | ||
{{FDA}} | |||
[[Category:Drugs]] | |||
Revision as of 03:37, 15 February 2009
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overdose
There is no known antidote for Arixtra Injection. Overdose of Arixtra may lead to hemorrhagic complications. Overdosage associated with bleeding complications should lead to treatment discontinuation and initiation of appropriate therapy.
Data obtained in patients undergoing chronic intermittent hemodialysis suggest that clearance of Arixtra can increase by 20% during hemodialysis.
Adapted from the FDA Package Insert.